ADVerse outcome Network for non mutagenic CarcinogEns
The field of toxicology is evolving from purely descriptive to a highly data‐rich science. To structure this large amount of data and in this way make the usage more effective for the safety assessors, the concept of adverse outco...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RISK-HUNT3R
RISK assessment of chemicals integrating HUman centric Next...
23M€
Cerrado
AXLR8
Accelerating the transition to a toxicity pathway based para...
613K€
Cerrado
NOTOX
Predicting long term toxic effects using computer models bas...
10M€
Cerrado
EU-ToxRisk
An Integrated European Flagship Program Driving Mechanism...
30M€
Cerrado
BIO2014-54404-R
APROXIMACIONES DE SISTEMAS A LA PREDICCION AVANZADA DE LA SE...
109K€
Cerrado
Información proyecto ADVaNCE
Duración del proyecto: 24 meses
Fecha Inicio: 2017-09-04
Fecha Fin: 2019-09-30
Líder del proyecto
IQ Consult GmbH
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
187K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The field of toxicology is evolving from purely descriptive to a highly data‐rich science. To structure this large amount of data and in this way make the usage more effective for the safety assessors, the concept of adverse outcome pathways was established providing a means of understanding how chemicals induce adverse effects through their toxicity pathways and modes of action. However, there are some doubts if the one initiating event - one adverse outcome relationship enforced on AOPs by the OECD guideline is able to cover more complex adverse effects like hepatocellular carcinoma resulting from non-mutagenic chemical exposure. Therefore, the ADVaNCE project will demonstrate based on the just mentioned example that combining all existing knowledge into an adverse outcome network formed by interlinked AOPs is needed to cover all the pathways and intervention points activated in order to contribute to the development of hepatocellular carcinomas. Computational approaches will be used to extract important key events and their relationships from existing data sources and the relevant literature. These will be compared with existing AOPs and further experimental validation will be started. The computational and experimental result will finally guide the development of an integrated testing strategy completely based on in silico and in vitro data, which development and validation regarding regulatory usage will be continued after the project.